RUNX1 and acute myeloid leukemia: In contrast, in RUNX1 mutant-expressing cells derived from an ELANE mutant patient, a slight increase in inflammatory responses (e.g., IFN-γ signaling) was observed compared with ev controls, which was associated with leukemic progression in the mouse model and SCN-AML patient (compare Figure S6B with Figures 1F and 4).